Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia

About this update from Adagio Medical Holdings, Inc

[{"type":"text","content":"Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company’s First and Next Generation Proprietary Ultralow Cryoablation Technologies","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"LAGUNA HILLS, Calif., October 20, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors.","length":536,"tagName":"p"},{"type":"text","content":"Adagio intends to deploy the net proceeds to:","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Support submission activities for its FULCRUM-VT pivotal clinical study for Premarket (PMA) approval of the vCLAS™ ULTC System by the U.S. Food and Drug Administration ("FDA")","length":185,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Advance clinical experience and FDA submission activities for the Company’s faster, smaller, more flexible next generation ULTC catheter","length":136,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Build awareness of ULTC and its many advantages as a purpose-built solution for VT patients and the ventricular anatomy","length":119,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expand manufacturing and scale commercial-readiness","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strengthen overall corporate operations","length":39,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":530,"olType":false},{"type":"text","content":"The Company anticipates that this infusion of capital will de-risk execution and extend the Company’s cash runway into key inflection points.","length":141,"tagName":"p"},{"type":"text","content":""Closing this financing on the heels of sharing the acute results from our FULCRUM-VT clinical study at the recent VT Symposium is further validation of the positive feedback we received both from the podium and ...

More updates from Adagio Medical Holdings, Inc